Usted buscó: agomelatine (Inglés - Maltés)

thymanax agomelatine
thymanax agomelatina

potential interactions affecting agomelatine
interazzjonijiet li potenzjalment jaffettwaw agomelatine

the active substance is agomelatine.
is-sustanza attiva hi agomelatine.

objectives of agomelatine educational plan:
oġġettiv tal- pjan edukattiv t’ agomelatine:

responder rate analysis favoured agomelatine.
analiżi tar-rata ta’ rispons iffavorixxiet lill-agomelatine.

each tablet contains 25 mg of agomelatine.
kull pillola fiha 25 mg t ’ agomelatine.

1.1% on agomelatine 25/ 50 mg vs.
1. 1% b ’ agomelatine 25/ 50 mg vs 0. 7% bi plaċebo).

thymanax 25 mg film-coated tablets agomelatine
thymanax 25 mg pilloli miksija b’rita agomelatine

there is limited experience with agomelatine overdose.
l-esperjenza hija limitata b’doża eċċessiva t’agomelatine.

switching therapy from ssri/snri antidepressant to agomelatine
il-qlib tat-terapija minn antidipressanti ssri/snri għal agomelatine

potential for agomelatine to affect other medicinal products
l-effett potenzjali t’agomelatine fuq prodotti mediċinali oħra

each film-coated tablet contains 25 mg of agomelatine.
kull pillola miksija b’rita fiha 25 mg t’agomelatine.

agomelatine passes into the placenta and foetuses of pregnant rats.
agomelatine jgħaddi fil-plaċenta u l-feti ta’ firien tqal.

for agomelatine, no clinical data on exposed pregnancies are available.
m’ hemm l- ebda informazzjoni klinika provduta ta ’ l- effett t’ agomelatine fuq it- tqala.

there is no data on the influence of race on agomelatine pharmacokinetics.
m’hemmx informazzjoni fuq l-influwenza ta’ razza fuq il-farmakokinetika t’agomelatine.

agomelatine is rapidly and well (≥ 80%) absorbed after oral administration.
agomelatine jiġi assorbit malajr u tajjeb (≥ 80%) wara li jittieħed mill- ħalq.

agomelatine inhibits neither cyp1a2 in vivo nor the other cyp450 in vitro.
agomelatine ma jimpedixxix la cyp1a2 in vivo lanqas cyp450 oħrajn in vitro.

agomelatine is rapidly and well ( 80%) absorbed after oral administration.
agomelatine jiġi assorbit malajr u tajjeb (≥ 80%) wara li jittieħed mill-ħalq.

therefore, agomelatine will not modify exposure to medicinal products metabolised by cyp 450.
għalhekk, agomelatine ma jimmodifikax l-effetti ta’ prodotti mediċinali oħra metabolizzati b’cyp 450.

in the therapeutic dose-range, agomelatine systemic exposure increases proportionally with dose.
fil-livell tad-doża terapewtika l-esponiment sistemiku għall-agomelatine jiżdied proporzjonalment mad-doża.